Macopharma has built on its expertise in non-woven materials to expand its product range, above all for filtration applications. During the avian flu pandemic in 2005, the company set up a facility used exclusively to manufacture respirators. In this particular market, the French government selected Macopharma as one of its five official suppliers.
In 2007, the customer portfolio was diversified to serve industrial users, B-to-B customers and healthcare providers. Macopharma currently sells valved and unvalved FFP1, FFP2 and FFP3 respiratory protective devices that comply with three classes of filtration efficiency requirements under standard EN 149:2009. The company also manufactures a range of high-filtration surgical masks in four sizes, with polypropylene elastic ear loops.
During the 2009 H1N1 flu pandemic, the facility’s workforce was ramped up to 175 employees to be able to respond to the French government’s additional needs.
In 2011, Macopharma began expanding its range of masks aimed primarily at healthcare professionals. Its new range of surgical and pediatric masks with double certification delivers improved breathability while meeting both the highest industry standards and the needs of users.